Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CryoLife, Inc.
The Ascyrus Medical Dissection Stent is designed to help remodel the aortic arch following an aortic dissection. CryoLife will pay up to $200m for Ascyrus.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Private Company Edition: VC deals are surging this year for cell and gene therapy firms, according to ARM’s third quarter report. Also, Vivo Capital and the CF Foundation plan to invest nearly $2bn in health care and life science opportunities, and Akeso completes $150m series D.
Former Medivation CEO David Hung launched stealthy oncology start-up Nuvation with $275m in series A venture capital, while Tenaya's series B brought in $92m for small molecules as well as cell and gene therapies to treat cardiovascular diseases.
- Implantable Devices
- Other Names / Subsidiaries
- Cardiogenesis Corporation
- CryoLife Asia Pacific, Pte. Ltd.
- CryoLife Europa Ltd
- CryoLife France, SAS
- JOTEC AG
- JOTEC Cardiovascular SL.
- JOTEC Polska Sp. z o.o.
- JOTEC s.r.l.
- On-X Life Technologies Holdings, Inc.
- Ascyrus Medical LLC